Genmab — August 2020

[E_L]

No news yet from ADCT "Announced FDA lifted partial clinical hold on pivotal Phase 2 trial of Cami for relapsed or refractory Hodgkin lymphoma: In July 2020, the Company announced that the FDA had lifted the partial clinical hold on its pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami, formerly ADCT-301) in patients with relapsed or refractory Hodgkin lymphoma (HL).

[E_L]

The Company continued to treat those patients who could benefit from ongoing treatment during the partial clinical hold, and the clinical trial is now open for enrollment. Interim results from the clinical trial are expected in the first half of 2021, subject to any impact by COVID-19. The clinical trial is intended to support the submission of a BLA to the FDA."

[BioShare]

Ja, det er møgirriterende Pens. Gode ideer til et bearcertifkat i USD?

[Legolas23]

Det kunne være et godt emne i debatforummet, som er beregnet til det

[E_L]

guessing banks are positioning for capital increase after close/ warrant sales tomorrow. Would be nice to screw them with the ofatumumab approval tonight

[AaBforever]

That would be nice:-)

[lahn1]

Martin Hutchings og patient i Go´ aften Live TV2.

[E_L]

dough
@semodough
$ADCT catalysts from Cami in 2H
ADCT is planning to present at two medical conferences in 2H. We expect PK/PD data of Cami in solid tumors at ESMO in Sept. Interim pivotal ph 2 catcHLight data (n=47) of Cami in Hodgkin's lymphoma (HL) would be at ASH (Dec. 5th-8th).

[KWC]

Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement

Copenhagen, Denmark; August 18, 2020 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 62,716 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

[KWC]

400 shares at DKK 31.75,
6,500 shares at DKK 40.41,
1,500 shares at DKK 67.50,
47,438 shares at DKK 225.90,
50 shares at DKK 231.50,
850 shares at DKK 337.40,
2,000 shares at DKK 466.20,
275 shares at DKK 623.50,
250 shares at DKK 636.50,
1,175 shares at DKK 815.50,
1,150 shares at DKK 939.50, and
1,128 shares at DKK 1,145.00.

[bikube]

16 mio. i kassen og en udvanding på 0,1%. Det kunne da have været meget værre.

[GeorgeBest]

Artikel om epcoritamab fra Rigshospitalets hjemmeside (samme tema som fra BT) https://www.rigshospitalet.dk/presse-og-nyt/nyheder/nyheder/Sider/2020/august/banebrydende-antistofbehandling-for-lymfekraeft-vinder-frem.aspx

[bikube]

Pensionisten - De helt gamle warrants (op til 10 år) er ved at være slut. Nu må warrants kun blive 7 år, hvorefter de udløber, hvis de ikke er brugt.

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

God morgen.

[Helge_LarsenPI-redaktør]

Darzalex salg for juli USD 218,2.

[AaBforever]

Nå...mon vi ikke snart ser bunden af kanalen..;-)

[AaBforever]

Helge..er det godt eller?

[E_L]

ADC Therapeutics SA (ADCT) CEO Christopher Martin on Q2 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4369596-adc-therapeutics-sa-adct-ceo-christopher-martin-on-q2-2020-results-earnings-call-transcript?part=single

[Mcjean]

x med 12 og x herefter med 2(måske 2.3 ROW) så har du groft sagt resultatet for i år, hvilket springer samtlige estimater og vel betyder at der er vildt meget upside-risiko i aktien, som medfører at Nordea må opjustere med 7.75, mens vi andre åbner en flaske "sprudlewasser".